奥曲肽联合乌司他丁用于急性胰腺炎治疗的临床疗效观察

Clinical observation of octreotide combined with ulinastatin in the treatment of acute pancreatitis

目的观察奥曲肽联合乌司他丁用于急性胰腺炎治疗的临床疗效分析。方法 90例急性胰腺炎患者,采取随机数字表法分为对照组与实验组,各45例。对照组患者采取乌司他丁治疗,实验组患者采取奥曲肽联合乌司他丁治疗。比较两组治疗前后C反应蛋白(CRP)、血淀粉酶水平、临床症状消失时间、临床治疗效果、并发症发生率。结果治疗后,两组CRP与血淀粉酶水平均明显下降,且实验组CRP(22.22±2.35)mg/L、血淀粉酶(126.16±13.37)U/L均低于对照组的(30.62±2.95)mg/L、(142.42±15.16)U/L,差异有统计学意义(P<0.05)。实验组患者恶心呕吐、腹膜刺激征、腹胀、腹痛消失时间均短于对照组,差异有统计学意义(P<0.05)。实验组患者临床治疗总有效率为93.33%,高于对照组的73.33%,差异有统计学意义(P<0.05)。实验组患者并发症发生率为8.89%,与对照组的6.67%比较,差异无统计学意义(P>0.05)。结论在急性胰腺炎患者的治疗中,采取奥曲肽联合乌司他丁治疗,可明显的降低患者机体内炎性指标与血淀粉酶指标水平,在较为安全的前提下,获得较高治疗总有效率,效果理想。

Objective To observe the clinical efficacy of octreotide combined with ulinastatin in the treatment of acute pancreatitis. Methods A total of 90 patients with acute pancreatitis were divided into control group and experimental group according to random numerical table, with 45 cases in each group. The C-reactive protein(CRP) and blood amylase levels before and after treatment, disappearance time of clinical symptoms, clinical effects, and incidence of complications were compared between the two groups. Results After treatment, CRP and blood amylase levels were obviously decreased, and the CRP(22.22±2.35) mg/L and blood amylase(126.16±13.37) U/L of the experimental group were lower than(30.62±2.95) mg/L and(142.42±15.16) U/L of the control group, and the difference was statistically significant(P<0.05). The disappearance time of nausea and vomiting, peritoneal irritation, abdominal distension, abdominal pain of the experimental group were shorter than those of the control group, and the difference was statistically significant(P<0.05). The total effective rate of clinical treatment of the experimental group was 93.33%, which was higher than 73.33% of the control group, and the difference was statistically significant(P<0.05). The incidence of complications of the experimental group was 8.89%, which had no statistically significant difference compared with 6.67% of the control group(P>0.05). Conclusion Octreotide combined with ulinastatin can significantly reduce the level of inflammatory indicators and blood amylase indicators in patients with acute pancreatitis, so as to obtain a higher total effective rate of treatment under the premise of safety, and the effect is ideal.